AbbVie Inc. is 238.3x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($397.12 B vs $1.67 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | VRDN | ABBV |
|---|---|---|
| Market cap | $1.67 B | $397.12 B |
| US-listed rank | #2250 | #30 |
| Revenue (latest FY) | $70.85M | $61.16B |
| Net income (latest FY) | -$342.60M | $4.23B |
| Net margin | -483.6% | 6.9% |
| P/E (trailing FY) | - | 94.0 |
| SEC filings | 794 | 1,008 |
AbbVie Inc. is 238.3x more valuable than Viridian Therapeutics, Inc.DE by market capitalization ($397.12 B vs $1.67 B).
In their latest fiscal years, Viridian Therapeutics, Inc.DE reported $70.85M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Viridian Therapeutics, Inc.DE and AbbVie Inc., or browse the full rankings.